Lijenta 5 Tablet
by Nipro JMI Pharma Ltd
৳22.00
Opsonin Pharma Limited
Linagliptin is used to enhance glycemic control in individuals with type 2 diabetes mellitus.
Linagliptin is used to enhance glycemic control in people with type 2 diabetes. Linagliptin is a DPP-4 (dipeptidyl peptidase-4) inhibitor, which is an enzyme that destroys the incretin hormones GLP-1 (glucagon like peptide-1) and GIP (glucose dependent insulinotropic polypeptide). Thus, linagliptin raises the concentrations of active incretin hormones in the blood, increasing the release of insulin from pancreatic beta () cells in a glucose-dependent manner while reducing glucagon production from pancreatic alpha () cells.
Linagliptin is a mild competitive and weak to moderate mechanism-based inhibitor of the CYP isozyme CYP3A4, however it has no effect on the other CYP isozymes. The risk of clinically important interactions with other medications is minimal, and linagliptin had no clinically relevant influence on the pharmacokinetics of metformin, glyburide, simvastatin, warfarin, digoxin, or oral contraceptives in clinical trials.
Hypersensitivity to the active ingredient or any of the excipients
In combination with metformin and sulfonylurea, there is a risk of hypoglycemia, nasopharyngitis, cough, and pancreatitis.
Pregnancy classification B. In pregnant women, there are no appropriate and well-controlled trials. As a result, Linagliptin tablets should only be taken during pregnancy if absolutely necessary. It is unknown whether Linagliptin is excreted in breast milk.
Hypersensitivity to the active ingredient or any of the excipients
Keep away from light and heat in a dry area. Keep out of children's reach.
by Aristopharma Ltd.
৳22.00